About
SiSaf is delivering on the promise of RNA therapeutics to transform the treatment of disease
Our Story
SiSaf was founded in 2008 by biomaterials scientist, Dr Suzanne Saffie Siebert, with the vision of a new generation of hybrid drug delivery technology that combines the advantages of organic and inorganic drug carriers while overcoming their disadvantages. She discovered that silicon could be used to stabilize lipid nanoparticles and that in turn lipids help control the biodegradation of silicon. This led to the development of SiSaf’s Bio-Courier® platform.
Bio-Courier® has been licensed to industrial partners for use with a range of different molecules. A partnered Alopecia program has completed a Phase 2 trial meeting all safety and efficacy endpoints.
In our in vitro work with nucleic acids, Bio-Courier® delivered strong protein expression data, and the same carrier chemistry works in vivo. This inspired us to create Bio-Courier® TL – a research reagent for both in vitro and in vivo work. To be launched soon.
Our IP
SiSaf has built a continuously growing patent portfolio for both its pipeline and its technology.
A comprehensive patent landscape review by UK and U.S. patent attorneys concluded that SiSaf’s Bio-Courier technology is unencumbered by third-party rights and provides extensive freedom to operate.
Management Team
Dr. Suzanne Saffie-Siebert
Founder and CEO
Inventor/co-inventor of numerous drug delivery patents
Has held leadership roles in the pharmaceutical industry for 20+ years (Director of Research at pSiMedica Ltd and Head of the Drug Delivery Centre at Dompé SpA, Italy)
PhD from the School of Pharmacy at the University of London
Mike Mulqueen
Commercial Director
30+ years in big pharma and biotech
Senior alliance management roles with Roche
Senior business development positions with Silence Therapeutics and eTheRNA.
Led due diligence and negotiating teams in over 30 major deals
Dr. Michael Welsh
Chief Scientific Officer
25+ years of diversified biological sciences experience (microbiology, immunology, vaccines, diagnostics)
Former Head of the Virology Department of a UK government research institute
PhD from Queen’s University, Belfast
Dr. Nissim Torabi-Pour
Chief Technical Officer
Senior project management roles with biotech companies in UK and New Zealand
Research positions at the Mayo Clinic, USA, and Jena University, Germany
PhD from Queen Mary University of London
Andy Gibson
Head of Manufacture & Supply
Worked on projects worth over $100M and led operational teams of up to 150
Extensive experience in process/product development and product transfers
Management Team
Dr. Suzanne Saffie-Siebert
Founder and CEO
Inventor/co-inventor of numerous drug delivery patents
Has held leadership roles in the pharmaceutical industry for 20+ years (Director of Research at pSiMedica Ltd and Head of the Drug Delivery Centre at Dompé SpA, Italy)
PhD from the School of Pharmacy at the University of London
Mike Mulqueen
Commercial Director
Senior alliance management roles with Roche
Senior business development positions with Silence Therapeutics and eTheRNA.
Led due diligence and negotiating teams in over 30 major deals
Dr. Michael Welsh
Chief Scientific Officer
Former Head of the Virology Department of a UK government research institute
PhD from Queen’s University, Belfast
Dr. Nissim Torabi-Pour
Chief Technical Officer
Senior project management roles with biotech companies in UK and New Zealand
Research positions at the Mayo Clinic, USA, and Jena University, Germany
PhD from Queen Mary University of London
Andy Gibson
Head of Manufacture & Supply
Worked on projects worth over $100M and led operational teams of up to 150
Extensive experience in process/product development and product transfers
Board
Dr. Suzanne Saffie-Siebert
Founder and CEO
Inventor/co-inventor of numerous drug delivery patents
Has held leadership roles in the pharmaceutical industry for 20+ years (Director of Research at pSiMedica Ltd and Head of the Drug Delivery Centre at Dompé SpA, Italy)
PhD from the School of Pharmacy at the University of London
Dr. Richard Goodfellow
Board Member
Former CEO of immuno-oncology company Scancell and Founder of functional genomics company Paradigm Therapeutics
PhD from University of Liverpool
Dr. Finian Tan
Board Member
20+ years in banking and venture capital
Former Managing Director at Credit Suisse First Boston
Largest investor and shareholder of Baidu as Managing Director and Head of Asia for DFJ ePlanet
Former Deputy Secretary of the Ministry of Trade and Industry of Singapore
PhD from Cambridge University and D.Univ from Glasgow University
Dr. Elkhalil Binebine
Board Member
Financier and investor for 30+ years
Previously, he was a practising M.D. and personal physician to Malcolm Forbes
MD from La Sorbonne
Dr. Damian Kelly
Board Member
20+ years in business development and leadership roles at Croda
PhD from Cambridge University
Eric M. Attias
Board Member
30+ years in finance & institutional investment
Founder of Forepont Capital Partners
Co-Founder of $4 bn Nexar Capital Group (sold to bank UBP)
CEO & board member of $10 bn AUM Société Générale Asset Management Inc.
CEO & board member of $15 bn AUM bank UBP LLC
MBA from Columbia University
Neil Simms
Board Member
20+ years in investment management
Trained and qualified as Chartered Accountant with Ernst & Young
Tim Brundle
Board Member
Director of Research and Impact at Ulster University
Chief Executive Officer of Innovation Ulster Ltd
Executive MBA and Master of Medical Science from Queen’s University, Belfast
Board
Dr. Suzanne Saffie-Siebert
Founder and CEO
Inventor/co-inventor of numerous drug delivery patents
Has held leadership roles in the pharmaceutical industry for 20+ years (Director of Research at pSiMedica Ltd and Head of the Drug Delivery Centre at Dompé SpA, Italy)
PhD from the School of Pharmacy at the University of London
Dr. Richard Goodfellow
Board Member
Former CEO of immuno-oncology company Scancell and Founder of functional genomics company Paradigm Therapeutics
PhD from University of Liverpool
Dr. Finian Tan
Board Member
Founder and Chairman of Vickers Venture Partners
20+ years in banking and venture capital
Former Managing Director at Credit Suisse First Boston
Largest investor and shareholder of Baidu as Managing Director and Head of Asia for DFJ ePlanet
Former Deputy Secretary of the Ministry of Trade and Industry of Singapore
PhD from Cambridge University and D.Univ from Glasgow University
Dr. Elkhalil Binebine
Board Member
Financier and investor for 30+ years
Previously, he was a practising M.D. and personal physician to Malcolm Forbes
MD from La Sorbonne
Dr. Damian Kelly
Board Member
20+ years in business development and leadership roles at Croda
PhD from Cambridge University
Eric M. Attias
Board Member
Founder of Forepont Capital Partners
Co-Founder of $4 bn Nexar Capital Group (sold to bank UBP)
CEO & board member of $10 bn AUM Société Générale Asset Management Inc.
CEO & board member of $15 bn AUM bank UBP LLC
MBA from Columbia University
Neil Simms
Board Member
20+ years in investment management
Trained and qualified as Chartered Accountant with Ernst & Young
Tim Brundle
Board Member
Director of Research and Impact at Ulster University
Chief Executive Officer of Innovation Ulster Ltd
Executive MBA and Master of Medical Science from Queen’s University, Belfast
